Last reviewed · How we verify
liposomal bupivicaine
At a glance
| Generic name | liposomal bupivicaine |
|---|---|
| Also known as | Exparel, exparel, Ai Heng Ping |
| Sponsor | United States Naval Medical Center, San Diego |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant (PHASE4)
- Post Operative Infusion Pump Pain Study (PHASE4)
- Comparison of Liposomal Bupivacaine Versus Ropivacaine in Alleviating Rebound Pain (PHASE4)
- Exparel Versus Bupivacaine in Post-operative Pain Control (PHASE4)
- Local Anesthetic as Single Shot Versus Catheter in Patients Undergoing Video Assisted Thoracoscopic Surgery (PHASE2)
- Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery (PHASE3)
- Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain (PHASE4)
- Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- liposomal bupivicaine CI brief — competitive landscape report
- liposomal bupivicaine updates RSS · CI watch RSS
- United States Naval Medical Center, San Diego portfolio CI